Last reviewed · How we verify
KW-136
KW-136 is an investigational therapeutic agent in phase 3 development by Kawin Technology.
At a glance
| Generic name | KW-136 |
|---|---|
| Also known as | Coblopasvir |
| Sponsor | Kawin Technology Share-holding Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Limited public information is available on KW-136's specific mechanism of action. As a phase 3 candidate from Kawin Technology, it represents an advanced-stage investigational compound, but detailed mechanistic data has not been widely disclosed in accessible pharmaceutical databases or literature.
Approved indications
Common side effects
Key clinical trials
- KW-136 With Sofosbuvir for Chinese Adults With Chronic Hepatitis C (PHASE3)
- Safety and Efficacy of KW-136 and Sofosbuvir for Treatment of Chronic Hepatitis C (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KW-136 CI brief — competitive landscape report
- KW-136 updates RSS · CI watch RSS
- Kawin Technology Share-holding Co., Ltd. portfolio CI